What is Ispecimen Inc.'s earnings per share (EPS)?

Ispecimen Inc. (ISPC) reported diluted earnings per share of $-2.28 for fiscal year 2025. This represents a 87.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ispecimen Inc. Financials

ISPC

Source SEC Filings (10-K/10-Q) Updated Apr 1, 2026 Currency USD FYE April

This page shows Ispecimen Inc. (ISPC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.40x

For every $1 of reported earnings, Ispecimen Inc. generates $0.40 in operating cash flow (-$4.2M OCF vs -$10.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-4606.4x

Ispecimen Inc. earns $-4606.4 in operating income for every $1 of interest expense (-$9.0M vs $2K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.9M

YoY-79.2%

5Y CAGR-25.1%

Ispecimen Inc. generated $1.9M in revenue in fiscal year 2025. This represents a decrease of 79.2% from the prior year.

EBITDA

-$7.2M

YoY+30.5%

Ispecimen Inc.'s EBITDA was -$7.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 30.5% from the prior year.

Net Income

-$10.5M

YoY+16.1%

Ispecimen Inc. reported -$10.5M in net income in fiscal year 2025. This represents an increase of 16.1% from the prior year.

EPS (Diluted)

$-2.28

YoY+87.0%

Ispecimen Inc. earned $-2.28 per diluted share (EPS) in fiscal year 2025. This represents an increase of 87.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$4.2M

YoY+48.9%

Ispecimen Inc. generated -$4.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 48.9% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

30M

YoY+1648.0%

Ispecimen Inc. had 30M shares outstanding in fiscal year 2025. This represents an increase of 1648.0% from the prior year.

Margins & Returns

Gross Margin

1.3%

YoY-41.7pp

5Y CAGR-54.9pp

Ispecimen Inc.'s gross margin was 1.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 41.7 percentage points from the prior year.

Operating Margin

-465.4%

YoY-328.4pp

5Y CAGR-436.0pp

Ispecimen Inc.'s operating margin was -465.4% in fiscal year 2025, reflecting core business profitability. This is down 328.4 percentage points from the prior year.

Net Margin

-543.7%

YoY-409.2pp

5Y CAGR-486.8pp

Ispecimen Inc.'s net profit margin was -543.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 409.2 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$454

YoY-98.6%

5Y CAGR+1.3%

Ispecimen Inc. invested $454 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 98.6% from the prior year.

ISPC Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.9M-79.2%	$9.3M-6.4%	$9.9M-4.6%	$10.4M-6.6%	$11.1M+36.1%	$8.2M
Cost of Revenue	$1.9M-64.1%	$5.3M+10.0%	$4.8M+1.3%	$4.8M-9.4%	$5.2M+46.4%	$3.6M
Gross Profit	$24K-99.4%	$4.0M-21.9%	$5.1M-9.5%	$5.6M-4.1%	$5.9M+28.0%	$4.6M
R&D Expenses	N/A	$1.5M-7.8%	$1.6M+9.9%	$1.5M+67.6%	$879K+175.4%	$319K
SG&A Expenses	$3.5M-42.8%	$6.1M+2.2%	$5.9M-14.4%	$6.9M+23.5%	$5.6M+134.0%	$2.4M
Operating Income	-$9.0M+29.5%	-$12.7M-14.0%	-$11.2M-9.7%	-$10.2M-71.9%	-$5.9M-146.2%	-$2.4M
Interest Expense	$2K-98.9%	$174K+986.0%	$16K-93.3%	$239K-88.6%	$2.1M+0.3%	$2.1M
Income Tax	N/A	N/A	N/A	$0	$0	$0
Net Income	-$10.5M+16.1%	-$12.5M-12.6%	-$11.1M-8.3%	-$10.2M-14.3%	-$9.0M-92.6%	-$4.7M
EPS (Diluted)	$-2.28+87.0%	$-17.58	$-24.55	$-1.16+44.5%	$-2.09	$-4.97

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$107K-85.1%	$713K-32.6%	$1.1M-28.3%	$1.5M-44.6%	$2.7M-7.0%	$2.9M+25.1%	$2.3M-11.1%	$2.6M
Cost of Revenue	$205K-53.9%	$444K-32.4%	$657K-50.4%	$1.3M-14.8%	$1.6M+9.1%	$1.4M+42.4%	$1.0M-29.9%	$1.4M
Gross Profit	-$98K-136.4%	$269K-32.8%	$400K+164.4%	$151K-86.3%	$1.1M-23.0%	$1.4M+11.6%	$1.3M+12.4%	$1.1M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$864K-8.9%	$948K+25.0%	$759K-62.4%	$2.0M+125.7%	$893K-15.4%	$1.1M-49.8%	$2.1M+67.5%	$1.3M
Operating Income	-$2.8M-55.4%	-$1.8M-11.2%	-$1.6M+71.9%	-$5.8M-242.5%	-$1.7M+21.8%	-$2.2M+27.3%	-$3.0M-4.5%	-$2.9M
Interest Expense	$2	N/A	$2K-98.8%	$157K+2038.3%	$7K+64.6%	$4K+0.2%	$4K0.0%	$4K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.8M-165.5%	-$1.0M+36.9%	-$1.7M+72.6%	-$6.0M-320.0%	-$1.4M+31.7%	-$2.1M+27.3%	-$2.9M+5.6%	-$3.1M
EPS (Diluted)	$-0.48-14.3%	$-0.42+40.8%	$-0.71	N/A	$-2.10	$-3.72+41.5%	$-6.36	N/A

ISPC Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$9.4M-40.9%	$15.8M-35.7%	$24.6M-31.1%	$35.7M+475.2%	$6.2M
Current Assets	N/A	$3.6M-56.4%	$8.2M-58.1%	$19.7M-40.3%	$32.9M+848.9%	$3.5M
Cash & Equivalents	N/A	$1.9M-19.9%	$2.3M-84.7%	$15.3M-44.8%	$27.7M+3886.0%	$696K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$1.4M+98.3%	$728K-54.4%	$1.6M-46.8%	$3.0M+96.7%	$1.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$6.0M-0.6%	$6.1M+41.1%	$4.3M-27.3%	$5.9M-82.3%	$33.5M
Current Liabilities	N/A	$5.8M-4.6%	$6.0M+41.3%	$4.3M+70.9%	$2.5M-88.7%	$22.1M
Long-Term Debt	N/A	N/A	N/A	N/A	$3.4M	N/A
Total Equity	N/A	$3.3M-66.0%	$9.7M-52.0%	$20.3M-31.8%	$29.8M+209.2%	-$27.3M
Retained Earnings	N/A	-$71.9M-21.1%	-$59.4M-23.0%	-$48.3M-26.9%	-$38.0M-30.8%	-$29.1M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$9.0M+49.1%	$6.0M-11.8%	$6.8M-26.8%	$9.4M-17.0%	$11.3M-5.4%	$11.9M-4.9%	$12.5M-20.9%	$15.8M
Current Assets	$3.6M+208.9%	$1.2M-23.7%	$1.5M-57.4%	$3.6M-23.0%	$4.7M-11.0%	$5.2M-1.0%	$5.3M-35.8%	$8.2M
Cash & Equivalents	$2.8M+372.6%	$589K-24.8%	$783K-58.3%	$1.9M+7.2%	$1.8M-18.6%	$2.2M+2.9%	$2.1M-10.8%	$2.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$121K-67.5%	$372K-36.0%	$582K-59.7%	$1.4M+48.3%	$974K+9.1%	$893K+104.1%	$437K-39.9%	$728K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.9M+9.5%	$5.4M+4.6%	$5.2M-14.3%	$6.0M-7.8%	$6.5M+12.7%	$5.8M+2.0%	$5.7M-6.2%	$6.1M
Current Liabilities	$5.7M+10.2%	$5.2M+5.1%	$4.9M-14.7%	$5.8M-7.9%	$6.3M+7.8%	$5.8M+2.0%	$5.7M-5.8%	$6.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.1M+394.0%	$622K-62.7%	$1.7M-49.6%	$3.3M-29.8%	$4.7M-22.6%	$6.1M-10.6%	$6.8M-30.1%	$9.7M
Retained Earnings	-$77.3M-3.7%	-$74.6M-1.4%	-$73.5M-2.3%	-$71.9M-9.2%	-$65.8M-2.2%	-$64.4M-3.4%	-$62.3M-4.9%	-$59.4M

ISPC Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$4.2M+48.7%	-$8.3M-42.3%	-$5.8M+0.2%	-$5.8M+45.5%	-$10.7M-3599.4%	-$288K
Capital Expenditures	$454-98.6%	$32K+62.0%	$19K-91.0%	$216K+8351.1%	$3K+498.6%	$426
Free Cash Flow	-$4.2M+48.9%	-$8.3M-42.4%	-$5.8M+3.4%	-$6.0M+43.5%	-$10.7M-3594.9%	-$289K
Investing Cash Flow	-$1.0M-150.5%	$2.0M+127.4%	-$7.2M-126.5%	-$3.2M-207.5%	-$1.0M+5.9%	-$1.1M
Financing Cash Flow	$10.2M+76.0%	$5.8M+8108.5%	$71K+102.1%	-$3.4M-108.8%	$38.7M+1806.0%	$2.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$2.0M-958.9%	-$192K+82.5%	-$1.1M+69.3%	-$3.6M-231.0%	-$1.1M+29.9%	-$1.5M+25.7%	-$2.1M-700.4%	$345K
Capital Expenditures	$0	N/A	N/A	$8K-45.9%	$15K	$0-100.0%	$9K	$0
Free Cash Flow	-$2.0M	N/A	N/A	-$3.6M-227.3%	-$1.1M+28.9%	-$1.5M+26.1%	-$2.1M-703.1%	$345K
Investing Cash Flow	-$1.0M	N/A	N/A	-$73K+59.4%	-$180K-161.0%	$295K-84.8%	$1.9M+368.0%	-$723K
Financing Cash Flow	$5.2M	N/A	N/A	$3.8M+338.6%	$860K-34.1%	$1.3M+1198.4%	-$119K	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$0	$0-100.0%	$53K	N/A

ISPC Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	1.3%-41.7pp	42.9%-8.5pp	51.4%-2.8pp	54.3%+1.4pp	52.9%-3.3pp	56.2%
Operating Margin	-465.4%-328.4pp	-137.0%-24.5pp	-112.5%-14.6pp	-97.9%-44.7pp	-53.2%-23.8pp	-29.4%
Net Margin	-543.7%-409.2pp	-134.5%-22.7pp	-111.8%-13.3pp	-98.5%-18.0pp	-80.5%-23.6pp	-56.8%
Return on Equity	N/A	-377.5%-263.5pp	-113.9%-63.5pp	-50.4%-20.4pp	-30.1%	N/A
Return on Assets	N/A	-133.7%-63.5pp	-70.2%-28.5pp	-41.6%-16.5pp	-25.1%+49.8pp	-74.9%
Current Ratio	N/A	0.62-0.7	1.36-3.2	4.60-8.6	13.15+13.0	0.16
Debt-to-Equity	N/A	1.82+1.2	0.62+0.4	0.21+0.1	0.11+1.3	-1.23
FCF Margin	-219.9%-130.6pp	-89.3%-30.6pp	-58.7%-0.7pp	-58.0%+37.8pp	-95.8%-92.3pp	-3.5%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	-91.9%-129.7pp	37.7%-0.1pp	37.9%+27.6pp	10.3%-31.4pp	41.6%-8.6pp	50.3%-6.1pp	56.3%+11.8pp	44.6%
Operating Margin	-2655.2%-2399.8pp	-255.4%-100.5pp	-154.9%+240.9pp	-395.8%-331.8pp	-64.1%+12.1pp	-76.2%+54.9pp	-131.0%-19.5pp	-111.5%
Net Margin	-2608.7%-2461.8pp	-146.8%+10.0pp	-156.8%+253.0pp	-409.8%-355.7pp	-54.1%+19.6pp	-73.7%+53.1pp	-126.7%-7.4pp	-119.3%
Return on Equity	-90.5%+77.9pp	-168.4%-69.0pp	-99.4%+83.2pp	-182.6%-152.1pp	-30.5%+4.1pp	-34.6%+8.0pp	-42.6%-11.0pp	-31.6%
Return on Assets	-30.9%-13.6pp	-17.3%+6.9pp	-24.2%+40.4pp	-64.7%-51.9pp	-12.8%+4.9pp	-17.7%+5.5pp	-23.2%-3.8pp	-19.4%
Current Ratio	0.63+0.4	0.23-0.1	0.31-0.3	0.62-0.1	0.74-0.2	0.90-0.0	0.93-0.4	1.36
Debt-to-Equity	1.93-6.8	8.70+5.6	3.10+1.3	1.82+0.4	1.39+0.4	0.95+0.1	0.84+0.2	0.62
FCF Margin	-1909.7%	N/A	N/A	-242.7%-201.6pp	-41.1%+12.7pp	-53.8%+37.2pp	-90.9%-104.3pp	13.4%

Similar Companies

Advanced Biomed Inc. ADVB

$6.2M

Mainz Biomed NV MYNZ

$10.6M

bioAffinity Tech BIAF

$17.6M

XWELL Inc XWEL

$6.2M

Prophase Labs Inc PRPH

$1.5M

Frequently Asked Questions

What is Ispecimen Inc.'s annual revenue?

Ispecimen Inc. (ISPC) reported $1.9M in total revenue for fiscal year 2025. This represents a -79.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Ispecimen Inc.'s revenue growing?

Ispecimen Inc. (ISPC) revenue declined by 79.2% year-over-year, from $9.3M to $1.9M in fiscal year 2025.

Is Ispecimen Inc. profitable?

No, Ispecimen Inc. (ISPC) reported a net income of -$10.5M in fiscal year 2025, with a net profit margin of -543.7%.

What is Ispecimen Inc.'s EBITDA?

Ispecimen Inc. (ISPC) had EBITDA of -$7.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Ispecimen Inc.'s gross margin?

Ispecimen Inc. (ISPC) had a gross margin of 1.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Ispecimen Inc.'s operating margin?

Ispecimen Inc. (ISPC) had an operating margin of -465.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Ispecimen Inc.'s net profit margin?

Ispecimen Inc. (ISPC) had a net profit margin of -543.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Ispecimen Inc.'s free cash flow?

Ispecimen Inc. (ISPC) generated -$4.2M in free cash flow during fiscal year 2025. This represents a 48.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Ispecimen Inc.'s operating cash flow?

Ispecimen Inc. (ISPC) generated -$4.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Ispecimen Inc.'s capital expenditures?

Ispecimen Inc. (ISPC) invested $454 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Ispecimen Inc. have outstanding?

Ispecimen Inc. (ISPC) had 30M shares outstanding as of fiscal year 2025.

Are Ispecimen Inc.'s earnings high quality?

Ispecimen Inc. (ISPC) has an earnings quality ratio of 0.40x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Ispecimen Inc. cover its interest payments?

Ispecimen Inc. (ISPC) has an interest coverage ratio of -4606.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.